RBCL Stock UPDATES RBC Life Sciences (RBCL) 0.7000 08/11/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
RBC Life Sciences (RBCL) 0.7000 $RBCL

Chairman and Chief Executive Officer of RBC Life Sciences Addresses Company Performance
PR Newswire - Thu Jun 12, 4:00PM CDT
RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products, today released the following letter which was sent to the Company's stockholders addressing recent performance.

RBC Life Sciences ' net loss widens to USD500,000 in 2013
M2 - Fri Mar 28, 6:45AM CDT
Nutritional supplements company RBC Life Sciences (Other OTC:RBCL) stated on Thursday its net loss of USD500,000 (USD0.23 per diluted share) for the year ended 31 December 2013.

RBC Life Sciences Reports 2013 Results
PR Newswire - Thu Mar 27, 8:00AM CDT
RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products, today reported consolidated net sales of $25.5 million for the year ended December 31, 2013, a 1% increase over 2012 consolidated net sales of $25.2 million. For the year ended December 31, 2013, the Company reported a net loss of $500,000, or $0.23 per diluted share, compared to a net loss of $361,000, or $0.16 per diluted share, during 2012.

RBC Life Sciences Announces Share Repurchase Program
PR Newswire - Wed Aug 28, 7:00AM CDT
RBC Life Sciences, Inc. (OTCQB: RBCLD), a provider of proprietary nutritional supplements, and wound care and pain management products (the "Company" , today announced that its Board of Directors approved a share repurchase program, authorizing the Company to repurchase in the aggregate up to 111,000 shares, representing 5% of the shares, of its currently outstanding common stock.

RBC Life Sciences Inc reports launch of reverse stock split & forward stock split
M2 - Mon Aug 12, 5:24AM CDT
Nutritional supplements company RBC Life Sciences Inc (RBCLD:OTC Markets) on Friday declared a one-for-500 reverse stock split of its common stock.

RBC Life Sciences Announces Stock Splits
PR Newswire - Fri Aug 09, 3:00PM CDT
RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products (the "Company" , today announced that it is effecting a 1-for-500 reverse stock split of the Company's Common Stock (the "Common Stock" , followed by a 50-for-1 forward stock split of the Common Stock (the "Stock Splits" as of the commencement of trading on the OTCQB on Monday, August 12, 2013. In addition, at the opening of the market on August 12, 2013, the Common Stock will trade under a new CUSIP number, 74926T 201. The Company's ticker symbol, RBCL, will be temporarily appended with a "D" for a period of 20 days to indicate the effectiveness of the Stock Splits.

RBC Life Sciences Reports Second Quarter Results
PR Newswire - Wed Aug 07, 1:00PM CDT
RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products, today reported consolidated net sales of $6.7 million for the second quarter of 2013, a 2% increase over the second quarter of 2012. For the second quarter of 2013, the Company reported a net loss of $147,000, or $0.01 per share, compared to net earnings of $320,000, or $0.01 per share, for the same quarter last year. Net sales were $12.4 million for the six months ended June 30, 2013, a 2% decrease over the same period in 2012. For the six months ended June 30, 2013, the Company reported a net loss of $155,000, or $0.01 per share, compared to net earnings of $247,000, or $0.01 per share for the comparable period in 2012.

RBC Life Sciences Reports First Quarter 2013 Results
PR Newswire - Wed May 15, 1:13PM CDT
RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products, today reported consolidated net sales of $5.7 million for the first quarter ended March 31, 2013, a 6% decrease over the first quarter ended March 31, 2012. For the first quarter of 2013, the Company reported a net loss of $8,000, or $0.00 per diluted share, compared to a net loss of $73,000, or $0.00 per diluted share, during the first quarter of 2012.

RBC Life Sciences wins US patent for Neurobright to improve cognitive function
M2 - Thu Jan 31, 9:17AM CST
Nutritional supplements company RBC Life Sciences Inc (OTC Markets:RBCL) reported on Wednesday the receipt of the US Patent 8357422 for its unique cognitive dietary supplement formulation, Neurobright.

US Patent Granted to RBC Life Sciences for Supplement that Supports Cognitive Function
PR Newswire - Wed Jan 30, 3:37PM CST
RBC Life Sciences, Inc. (OTCQB: RBCL) (the "Company" , has been granted US Patent 8357422, which protects its unique dietary supplement formulation that nutritionally supports cognitive function, learning and remembering. The Company markets this supplement under the name "Neurobright®." The grant of this patent evidences the Company's continued commitment to bring effective science-based dietary supplements to the market.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 325

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 129

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 42

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 241

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 343

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading

Top 5 Most Recently Viewed Articles

Anticipating NeuroOne's Q2 Financial Insights and Growth Strategies

Updated Category News Views 124

NeuroOne Prepares to Release Second Quarter Fiscal Financial Results EDEN PRAIRIE, Minn. — NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is set to unveil its financial performance for the fiscal second quarter. The reporting period ended on March 31, and the results will be publicized before market activities commence on May 13. This is an exciting time for...

Continue Reading
FNB's Grand Plan for Ultra-Rich Wealth Clients

Updated Category News Views 79

FNB Corporation's New Strategy Sparks Interest Ah, the ever-competitive world of financial services targets the well-heeled once again. FNB Corporation (NYSE: FNB), headquartered in Pittsburgh, is rolling up its sleeves to offer something new for ultra-high-net-worth clientele. Outside Wall Street's dizzying chaos, this quiet yet aggressive move seems to signal they're up...

Continue Reading
Brazil Stock Market Trends and Key Indicators Update

Updated Category News Views 300

Brazil Stock Market Overview Recently, Brazil's stock market showed signs of decline, particularly on a Thursday when the Bovespa index dropped by 0.79%, reaching a new three-month low. This downturn was primarily driven by losses in critical sectors such as Public Utilities, Electric Power, and Real Estate. Investors and market analysts closely monitor these trends as...

Continue Reading
NEXN Stock Reaches New Heights Amid Positive Market Trends

Updated Category News Views 159

NEXN Stock Hits New Milestone NEXN stock has recently hit a significant milestone, reaching a price of $8.34. This impressive peak is not just a reflection of the company’s strong performance but also highlights a period filled with optimism in the market. With investors closely monitoring the stock's path, this new high may point to a potential sustained upward trend...

Continue Reading
Total Voting Rights Update from PayPoint Plc

Updated Category News Views 108

Understanding PayPoint Plc's Total Voting Rights PayPoint Plc has recently provided an update regarding its voting rights and share capital, which is crucial information for shareholders and those interested in the company. Total Share Capital Information As of August 31, 2024, PayPoint Plc's share capital consists of 72,342,171 ordinary shares, each valued at 1/3 pence....

Continue Reading